ReviewNature reviews. Microbiology2023
Respiratory syncytial virus infection and novel interventions.
Review in Nature reviews. Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 105 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it, 157 citations in OpenAlex.
- Pooled it
- Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis.BMC public health · 2024Pooled it
- Immunogenicity, safety, and tolerability of a β-glucan-CpG-adjuvanted respiratory syncytial virus vaccine in Japanese healthy participants aged 60 to 80 years: A phase 2, randomized, double-blind, dose-finding study.Human vaccines & immunotherapeutics · 2025Trial
- Assessing the willingness and preference of pregnant and postpartum women regarding RSV immunization for newborns in western China: A mixed-methods study.Human vaccines & immunotherapeutics · 2026Article
- Respiratory Syncytial Virus Vaccination as Cardiopulmonary and Cardiovascular Risk Mitigation in Adults with Heart Disease.Journal of clinical medicine · 2026Review
- Computational approaches for flavivirus drug discovery: targeting structural and non-structural proteins.RSC medicinal chemistry · 2026Review
- Time-Multiplexed Organic Electrochemical Transistor for Saliva-Based Rapid Detection of Viral Proteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Triple IFN pathway deficiency sensitizes mice to human respiratory virus infection independent of human viral receptor expression.Nature communications · 2026Article
- Respiratory syncytial virus infection in adults: Clinical manifestations, outcomes, and vaccines.Journal of the Chinese Medical Association : JCMA · 2026Review
- Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.Virus research · 2026Article
- Live nontypeable Haemophilus influenzae exacerbates respiratory syncytial virus-associated lower airway inflammation.Respiratory research · 2026Article
- Respiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity.Science advances · 2026Article
- Dual inhibition of intercellular adhesion molecule-1 and nucleolin reduces RSV infection efficiency in human respiratory organoids.Molecular therapy. Nucleic acids · 2026Article
- ZFP91 restricts RSV replication by driving K48-linked ubiquitination and proteasomal degradation of M2-1.Cellular and molecular life sciences : CMLS · 2026Article
- Phylodynamics and molecular epidemiology of the respiratory syncytial virus fusion protein in China.Microbiology spectrum · 2026Article
- Predictive Model for Critical Illness Infection in Hospitalized Children with RSV Infection: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Intermediate Relative Humidity Preserves Respiratory Syncytial Virus via a Semi-Solid Bioaerosol State.bioRxiv : the preprint server for biology · 2026Article
- Structural Advances in Respiratory Syncytial Virus: Implications for Vaccine and Antiviral Development.Microorganisms · 2026Review
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in young children and older adults has gained increased recognition in recent years. Recent discoveries regarding the neutralization-specific viral epitopes of the pre-fusion RSV glycoprotein have led to a shift from empirical to structure-based design of RSV therapeutics, and controlled human infection model studies have provided early-stage proof of concept for novel RSV monoclonal antibodies, vaccines and antiviral drugs. The world's first vaccines and first monoclonal antibody to prevent RSV among older adults and all infants, respectively, have recently been approved. Large-scale introduction of RSV prophylactics emphasizes the need for active surveillance to understand the global impact of these interventions over time and to timely identify viral mutants that are able to escape novel prophylactics. In this Review, we provide an overview of RSV interventions in clinical development, highlighting global disease burden, seasonality, pathogenesis, and host and viral factors related to RSV immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.